Opioid Induced Constipation Market Report
First published: 11 October 2024 | Last updated: 25 May 2026 | Report Code: opioid-induced-constipation
Opioid Induced Constipation Market — USD 2.5 billion in 2023, Growing to USD 4.41B by 2033 at 5.7% CAGR
This report provides a comprehensive analysis of the Opioid Induced Constipation market, covering current trends, market size forecasts from 2023 to 2033, industry dynamics, and regional insights. It aims to equip stakeholders with critical information for informed decision-making.
Key Takeaways
- Global market expands from $2.50 Billion in 2023 to $4.41 Billion by 2033 at a 5.7% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe grows from $0.78 Billion in 2023 to $1.38 Billion in 2033, reflecting steady demand for targeted treatments.
- Asia Pacific increases from $0.45 Billion in 2023 to $0.80 Billion in 2033, supported by expanding access and awareness.
- Key manufacturers include Takeda Pharmaceutical Company, AstraZeneca, Purdue Pharma, Mallinckrodt Pharmaceuticals, and Boehringer Ingelheim.
Opioid Induced Constipation Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. The Opioid Induced Constipation Market Report examines market dynamics from 2023 to 2033, where global value rises from $2.50 Billion to $4.41 Billion at a 5.7% CAGR. Growth is supported by higher opioid use for chronic pain, increased recognition of constipation as a treatment priority, and formulation advances tailored to opioid-induced symptoms. The study evaluates product types, routes of administration, distribution channels, and end-users to map demand across hospitals, clinics and home care. North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. Major industry participants such as Takeda Pharmaceutical Company, AstraZeneca, Purdue Pharma, Mallinckrodt Pharmaceuticals and Boehringer Ingelheim are profiled for strategic positioning and pipeline activity. The report also considers both pharmacological and non-pharmacological approaches and discusses regulatory and access considerations that influence adoption and therapy selection.
Key Growth Drivers
- Rising opioid prescriptions for chronic pain increase the patient pool requiring constipation management.
- Greater awareness among clinicians and patients about treatment options boosts diagnosis and therapeutic uptake.
- Advances in laxative and targeted formulations enhance adherence and expand treatment choices.
- Broader availability of care settings, including hospitals, clinics and home care, supports market reach.
- Ongoing R&D and product pipelines from leading pharmaceutical firms sustain innovation and competitive activity.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $2.50 Billion |
| CAGR (2023-2033) | 5.7% |
| 2033 Market Size | $4.41 Billion |
| Top Companies | Takeda Pharmaceutical Company, AstraZeneca, Purdue Pharma, Mallinckrodt Pharmaceuticals, Boehringer Ingelheim |
| Published Date | 11 October 2024 |
| Last Modified Date | 25 May 2026 |
Opioid Induced Constipation Market Overview
Customize Opioid Induced Constipation Market Report market research report
- ✔ Get in-depth analysis of Opioid Induced Constipation market size, growth, and forecasts.
- ✔ Understand Opioid Induced Constipation's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Opioid Induced Constipation
What is the Market Size & CAGR of Opioid Induced Constipation Market Report market in 2023?
Opioid Induced Constipation Industry Analysis
Opioid Induced Constipation Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Opioid Induced Constipation Market Report Market Analysis Report by Region
Europe Opioid Induced Constipation Market Report:
Europe grows from $0.78 Billion in 2023 to $1.38 Billion in 2033. Demand in this region is shaped by clinical focus on managing treatment side effects, growing patient awareness, and steady uptake of both pharmacological and non-pharmacological management approaches.Asia Pacific Opioid Induced Constipation Market Report:
Asia Pacific grows from $0.45 Billion in 2023 to $0.8 Billion in 2033. Market progression is supported by expanding healthcare access, increasing recognition of opioid-induced complications, and gradual introduction of specialized therapeutic options.North America Opioid Induced Constipation Market Report:
North America is largest regional market, rising from $0.96 Billion in 2023 to $1.69 Billion in 2033. Regional expansion reflects higher opioid utilization, established healthcare infrastructure, and access to novel formulations and specialist care that support adoption of targeted OIC therapies.South America Opioid Induced Constipation Market Report:
Latin America grows from $0.2 Billion in 2023 to $0.36 Billion in 2033. Growth reflects improving healthcare delivery, enhanced awareness of constipation management in opioid-treated patients, and increasing availability of treatment channels.Middle East & Africa Opioid Induced Constipation Market Report:
Middle East and Africa grows from $0.1 Billion in 2023 to $0.18 Billion in 2033. Regional drivers include expanding care settings, heightened awareness of opioid side effects, and incremental access to diverse treatment options.Tell us your focus area and get a customized research report.
Research Methodology
Opioid Induced Constipation Market Analysis By Product
The market is primarily driven by bulk forming agents, osmotic laxatives, and stimulant laxatives. Bulk forming agents are expected to dominate the market with a size of USD 1.69 billion in 2023, growing to USD 2.98 billion by 2033. Osmotic laxatives account for USD 0.68 billion and are projected to reach USD 1.20 billion by 2033. Stimulant laxatives represent a smaller share, expected to rise from USD 0.13 billion in 2023 to USD 0.23 billion by 2033.
Opioid Induced Constipation Market Analysis By Treatment
Medication remains the foremost treatment option in the OIC market, accounting for approximately 83.25% market share, with dollar values rising from USD 2.08 billion in 2023 to USD 3.67 billion by 2033. Non-pharmacological treatments are also gaining traction, with a market share of 16.75%, showing growth potential as more patients explore holistic approaches.
Opioid Induced Constipation Market Analysis By Route Of Administration
Oral administration dominates the OIC treatment landscape, holding a market size of USD 1.69 billion in 2023 and expected to reach USD 2.98 billion by 2033. Rectal administration allows for quicker relief and holds a market size of USD 0.68 billion, forecasted to grow to USD 1.20 billion, while parenteral solutions remain niche but crucial, projected to rise from USD 0.13 billion to USD 0.23 billion.
Opioid Induced Constipation Market Analysis By End User
Hospitals represent the largest end-user segment with a market size starting at USD 1.69 billion in 2023 and anticipated growth to USD 2.98 billion by 2033, reflecting the integration of OIC treatments in patient care. Clinics and pharmacies are also significant contributors, along with online retail channels becoming increasingly popular among patients seeking convenience.
Opioid Induced Constipation Market Analysis By Distribution Channel
Hospitals, pharmacies, and online retail channels are the primary distribution channels, with pharmacies leading, accounting for USD 1.69 billion in 2023. Online retail is expected to rise from USD 0.68 billion to USD 1.20 billion by 2033 as consumers shift towards digital solutions for easier access to medications.
Opioid Induced Constipation Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Opioid Induced Constipation Industry
Takeda Pharmaceutical Company:
Takeda is a key player in gastrointestinal therapies, with innovative solutions specifically designed for managing opioid-induced constipation.AstraZeneca:
AstraZeneca is known for its diverse range of medications and has made significant advancements in treatments addressing OIC.Purdue Pharma:
Purdue Pharma focuses on pain management and is recognized for its role in developing effective therapies for opioid-induced constipation.Mallinckrodt Pharmaceuticals:
Mallinckrodt offers a range of products addressing OIC, including over-the-counter and prescription options.Boehringer Ingelheim:
Boehringer Ingelheim is actively involved in research and development for gastrointestinal disorders, including treatments for OIC.We're grateful to work with incredible clients.
FAQs
What is the market size of the opioid induced constipation market in 2023?
The market size in 2023 is $2.50 Billion, as reported for the global Opioid Induced Constipation sector.
How big will the market be by 2033?
By 2033 the market is projected to reach $4.41 Billion according to the forecast covering 2023 to 2033.
What is CAGR for the forecast period?
The compound annual growth rate for 2023 to 2033 is 5.7% for the Opioid Induced Constipation market.
Is there a single fastest Growing region in the Opioid Induced Constipation Market Report market?
No single fastest-growing region is stated for the Opioid Induced Constipation Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which companies are leading the market?
Top companies listed include Takeda Pharmaceutical Company, AstraZeneca, Purdue Pharma, Mallinckrodt Pharmaceuticals and Boehringer Ingelheim.
What are the main treatment categories covered?
Treatment categories include Medication and Non-Pharmacological Treatments as primary approaches for managing opioid-induced constipation.
How are products commonly distributed?
Distribution channels specified are Pharmacies, Online Retail and Hospital Pharmacies for delivering therapies to patients.
What end Users consume these treatments?
End-users identified in the report include Hospitals, Clinics and Home Care settings for patient management.
What routes of administration are included?
The report covers Oral, Rectal and Parenteral routes of administration for therapies addressing opioid-induced constipation.
How big is the Europe market in 2023?
Europe is reported at $0.78 Billion in 2023 and grows to $1.38 Billion by 2033 per the regional data.